ArticleBMC endocrine disorders2026
Time to first remission and associated factors in type 2 diabetes mellitus: a retrospective cohort study in Ethiopia.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of type 2 diabetes mellitus (T2DM) is rising in Ethiopia. Treatment for remission reduces further complications and the timing of these outcomes is influenced by various factors. However, there was a paucity of evidence in the Ethiopian context about these issues. This study examined the time to first remission and associated factors in T2DM patients treated at two referral hospitals in Eastern Ethiopia.
methodsA census-based retrospective cohort study was employed and analyzed secondary data from 1162 T2DM patients treated at two Hospitals between January 2017 and December 2021. Following descriptive analysis, Kaplan-Meier survival analysis was used to estimate the time to first remission, and Cox proportional hazards models were employed to identify factors associated with remission time.
resultsWithin a five-year follow-up period, 701 (60.33%) patients achieved first remission. Among those who achieved remission, 92.58% reached this milestone within the first 24 months of follow-up. Male gender, older age, family history of diabetes, comorbidities, increased cholesterol levels, and therapy at Dil-Chora Referral Hospital were all related to a longer duration of initial remission. Male gender was related to an 11.81% longer remission duration than females (HR = 0.8819, p = 0.006). Similarly, individuals with comorbidities had an 11.25% longer remission duration (HR = 0.8875, p < 0.001).
conclusionA significant majority of T2DM remissions occur within a critical two-year window following treatment initiation, identifying this period as the golden opportunity' for intensive clinical intervention. These findings underscore the necessity of implementing early, aggressive glycemic management and multidisciplinary care models to maximize remission potential. Future research should prioritize investigating the biological drivers of early treatment success and the long-term durability of remission in the Ethiopian context. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.